Figure 3 from Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer
<p>Auranofin increases the overall survival of OVCAR3 CDX mice. <b>A,</b><i>In vivo</i> imaging system spectrum <i>in vivo</i> images of tumor burden. Mice were treated with placebo, cisplatin, auranofin, or both drugs, following the regimen shown. Mice mark...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , |
| منشور في: |
2025
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| الملخص: | <p>Auranofin increases the overall survival of OVCAR3 CDX mice. <b>A,</b><i>In vivo</i> imaging system spectrum <i>in vivo</i> images of tumor burden. Mice were treated with placebo, cisplatin, auranofin, or both drugs, following the regimen shown. Mice marked with a red “X” in week 3 had little-to-no cancer cell uptake and were removed from data analysis in <b>B–G</b>. <b>B,</b> Tumor growth over time shown as mean normalized bioluminescence ± SEM for each treatment group (<i>n</i> = 4 mice per group at baseline). <b>C,</b> Raw <i>P</i> values plotted over time comparing cisplatin monotherapy with auranofin–cisplatin combination treatment. Statistical significance (red dot) was determined using multiple unpaired <i>t</i> tests. <b>D,</b> Magnified view of <b>B</b>, focusing on the cisplatin monotherapy and the combination treatment group (scaled between 0 and 1). <b>E,</b> Tumor burden for individual mice at week 5. Unpaired <i>t</i> tests were used for statistical comparison. <b>F,</b> AUC analysis of normalized tumor burden over time for each treatment group. Both tumor growth and shrinkage phases were quantified. Statistical comparisons were performed using one-way ANOVA with Holm–Šídák multiple comparisons. <b>G,</b> Kaplan–Meier survival analysis of each treatment group using humane endpoints. Statistical significance was determined by unpaired <i>t</i> tests. *, <i>P</i> < 0.05; **, <i>P</i> < 0.01; ****, <i>P</i> < 0.0001.</p> |
|---|